New app could help track muscle disease from your living room
NCT ID NCT05812144
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a mobile app (myFSHD) can help doctors monitor patients with facioscapulohumeral muscular dystrophy (FSHD) remotely. 70 adults with FSHD used the app at home for 12 months, completing questionnaires and video-recorded exercises. The goal was to see if patients would stick with the program and if the data collected is reliable compared to in-clinic assessments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- remote monitoring program (mobile app with questionnaires and exercises)
- What this could lead to
- If successful, this could provide reliable tools to monitor FSHD from home, making clinical trials easier and more patient-friendly.
- What could go wrong
- This is a small, completed feasibility study (70 people) focused on testing the app, not on treatment. It may not lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHRU de Lille
Lille, Hauts-de-France, 59000, France
-
CHU de Nice
Nice, Provence-Alpes-Côte d'Azur Region, 06000, France
-
Institut de Myologie
Paris, Île-de-France Region, 75013, France